{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:38:29Z","timestamp":1763707109006,"version":"build-2065373602"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04829-x","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:40:48Z","timestamp":1761154848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report"],"prefix":"10.1007","volume":"95","author":[{"given":"Reema","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Deeken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"12","key":"4829_CR1","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15(12):731\u2013747","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"4829_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11523-018-0590-1","volume":"13","author":"S Kummar","year":"2018","unstructured":"Kummar S, Lassen UN (2018) TRK inhibition: a new tumor-agnostic treatment strategy. Target Oncol 13(5):545\u2013556","journal-title":"Target Oncol"},{"issue":"8","key":"4829_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378(8):731\u2013739","journal-title":"N Engl J Med"},{"issue":"4","key":"4829_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol 21(4):531\u2013540","journal-title":"Lancet Oncol"},{"issue":"6","key":"4829_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/neuonc\/noab274","volume":"24","author":"F Doz","year":"2022","unstructured":"Doz F, Van Tilburg CM, Geoerger B, H\u00f8jgaard M, \u00d8ra I, Boni V et al (2022) Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncol 24(6):997\u20131007","journal-title":"Neuro-Oncol"},{"key":"4829_CR6","doi-asserted-by":"publisher","first-page":"e2100418","DOI":"10.1200\/PO.21.00418","volume":"6","author":"A Drilon","year":"2022","unstructured":"Drilon A, Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel JD et al (2022) Efficacy and safety of larotrectinib in patients with Tropomyosin receptor kinase Fusion-Positive lung cancers. JCO Precis Oncol 6:e2100418","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"4829_CR7","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1093\/oncolo\/oyac080","volume":"29","author":"X Le","year":"2024","unstructured":"Le X, Baik C, Bauman J, Gilbert J, Brose MS, Grilley-Olson JE et al (2024) Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers. Oncologist 29(6):e779\u2013e788","journal-title":"Oncologist"},{"key":"4829_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115338","volume":"220","author":"C Qi","year":"2025","unstructured":"Qi C, Shen L, Andre T, Chung HC, Cannon TL, Garralda E et al (2025) Efficacy and safety of larotrectinib in patients with TRK fusion Gastrointestinal cancer. Eur J Cancer 220:115338","journal-title":"Eur J Cancer"},{"issue":"9","key":"4829_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.annonc.2020.05.006","volume":"31","author":"D Liu","year":"2020","unstructured":"Liu D, Flory J, Lin A, Offin M, Falcon CJ, Murciano-Goroff YR et al (2020) Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol 31(9):1207\u20131215","journal-title":"Ann Oncol"},{"issue":"1","key":"4829_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/10781552241279196","volume":"31","author":"A Chin","year":"2025","unstructured":"Chin A, Lindsay S, Bergsland EK, Kang H (2025) Withdrawal pain following patients discontinuing Trk inhibitors. J Oncol Pharm Pract 31(1):147\u2013150","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"4829_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","volume":"72","author":"EJ Huang","year":"2003","unstructured":"Huang EJ, Reichardt LF (2003) Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72(1):609\u2013642","journal-title":"Annu Rev Biochem"},{"key":"4829_CR12","doi-asserted-by":"publisher","first-page":"viii5","DOI":"10.1093\/annonc\/mdz383","volume":"30","author":"A Amatu","year":"2019","unstructured":"Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S (2019) Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol 30:viii5-15","journal-title":"Ann Oncol"},{"issue":"1","key":"4829_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/(SICI)1097-4652(200001)182:1<127::AID-JCP14>3.0.CO;2-0","volume":"182","author":"A Greco","year":"2000","unstructured":"Greco A, Villa R, Fusetti L, Orlandi R, Pierotti MA (2000) The Gly571Arg mutation, associated with the autonomic and sensory disorder congenital insensitivity to pain with anhidrosis, causes the inactivation of the NTRK1\/nernerve growth factor receptor. J Cell Physiol 182(1):127\u2013133","journal-title":"J Cell Physiol"},{"issue":"4","key":"4829_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/ng0896-485","volume":"13","author":"Y Indo","year":"1996","unstructured":"Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T et al (1996) Mutations in the TRKA\/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet 13(4):485\u2013488","journal-title":"Nat Genet"},{"issue":"11","key":"4829_CR15","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/nn1336","volume":"7","author":"GSH Yeo","year":"2004","unstructured":"Yeo GSH, Connie Hung CC, Rochford J, Keogh J, Gray J, Sivaramakrishnan S et al (2004) A de Novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 7(11):1187\u20131189","journal-title":"Nat Neurosci"},{"key":"4829_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104234","volume":"194","author":"G Hagopian","year":"2024","unstructured":"Hagopian G, Nagasaka M (2024) Oncogenic fusions: targeting NTRK. Crit Rev Oncol Hematol 194:104234","journal-title":"Crit Rev Oncol Hematol"},{"issue":"41","key":"4829_CR17","doi-asserted-by":"publisher","first-page":"21363","DOI":"10.1074\/jbc.M116.722587","volume":"291","author":"ML Franco","year":"2016","unstructured":"Franco ML, Melero C, Sarasola E, Acebo P, Luque A, Calatayud-Baselga I et al (2016) Mutations in TrkA causing congenital insensitivity to pain with anhidrosis (CIPA) induce misfolding, aggregation, and mutation-dependent neurodegeneration by dysfunction of the autophagic flux. J Biol Chem 291(41):21363\u201321374","journal-title":"J Biol Chem"},{"issue":"8","key":"4829_CR18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nm0895-774","volume":"1","author":"SB Mcmahon","year":"1995","unstructured":"Mcmahon SB, Bennett DLH, Priestley JV, Shelton DL (1995) The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med 1(8):774\u2013780","journal-title":"Nat Med"},{"issue":"12","key":"4829_CR19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1080\/03007995.2019.1653068","volume":"35","author":"KM Kelly","year":"2019","unstructured":"Kelly KM, Sanga P, Zaki N, Wang S, Haeussler J, Louie J et al (2019) Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies. Curr Med Res Opin 35(12):2117\u20132127","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"4829_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2019.8044","volume":"322","author":"TJ Schnitzer","year":"2019","unstructured":"Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L et al (2019) Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA 322(1):37","journal-title":"JAMA"},{"issue":"2","key":"4829_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/papr.12342","volume":"16","author":"M Hirose","year":"2016","unstructured":"Hirose M, Kuroda Y, Murata E (2016) NGF\/TrkA signaling as a therapeutic target for pain. Pain Pract 16(2):175\u2013182","journal-title":"Pain Pract"},{"key":"4829_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114901","volume":"245","author":"S Tang","year":"2023","unstructured":"Tang S, Xue Y, Dengqi X, Shao L (2023) Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo. Eur J Med Chem 245:114901","journal-title":"Eur J Med Chem"},{"issue":"24","key":"4829_CR23","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1038\/sj.emboj.7600893","volume":"24","author":"X Zhang","year":"2005","unstructured":"Zhang X, Huang J, McNaughton PA (2005) NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 24(24):4211\u20134223","journal-title":"EMBO J"},{"issue":"4","key":"4829_CR24","first-page":"418","volume":"11","author":"DB Dunn","year":"2020","unstructured":"Dunn DB (2020) Larotrectinib and entrectinib: TRK inhibitors for the treatment of pediatric and adult patients with NTRK gene fusion. J Adv Pract Oncol 11(4):418\u2013423","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"4829_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdy539","volume":"30","author":"DS Hong","year":"2019","unstructured":"Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF et al (2019) Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol 30(2):325\u2013331","journal-title":"Ann Oncol"},{"key":"4829_CR26","unstructured":"Food & Drug Administration. OZEMPIC (semaglutide) injection, for subcutaneous use [Internet] (2023) Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215256s007lbl.pdf"},{"issue":"3","key":"4829_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/dom.14280","volume":"23","author":"M Friedrichsen","year":"2021","unstructured":"Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D (2021) The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 23(3):754\u2013762","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"4829_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-01979-4","volume":"26","author":"Y He","year":"2025","unstructured":"He Y, Xu B, Zhang M, Chen D, Wu S, Gao J et al (2025) Advances in GLP-1 receptor agonists for pain treatment and their future potential. J Headache Pain 26(1):46","journal-title":"J Headache Pain"},{"issue":"4","key":"4829_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s11154-023-09807-3","volume":"24","author":"N Garc\u00eda-Casares","year":"2023","unstructured":"Garc\u00eda-Casares N, Gonz\u00e1lez-Gonz\u00e1lez G, de la Cruz-Cosme C, Garz\u00f3n-Maldonado FJ, de Rojas-Leal C, Ariza MJ et al (2023) Effects of GLP-1 receptor agonists on neurological complications of diabetes. Rev Endocr Metab Disord 24(4):655\u2013672","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"4829_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocarto.2025.100567","volume":"7","author":"J Cheng","year":"2025","unstructured":"Cheng J, Solomon T, Estee M, Cicuttini FM, Lim YZ (2025) Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: a systematic review of pre-clinical and human studies. Osteoarthritis Cartilage Open 7(1):100567","journal-title":"Osteoarthritis Cartilage Open"},{"issue":"1","key":"4829_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C et al (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 9(1):234","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"4829_CR32","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1038\/s12276-024-01342-8","volume":"56","author":"EJ Go","year":"2024","unstructured":"Go EJ, Hwang SM, Jo H, Rahman MM, Park J, Lee JY et al (2024) GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation. Exp Mol Med 56(11):2449\u20132464","journal-title":"Exp Mol Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04829-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:40:49Z","timestamp":1761154849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04829-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4829"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04829-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Inova Health System has been provided financial support by the sponsor (first LOXO Oncology and then Bayer) for the clinical trial in which the patient was enrolled. Dr. Deeken was the site Principal Investigator of that study. He does not have any other interests related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"102"}}